Site Search
404 Results (showing 1 - 25)
The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.
Theranos Investors on the Line
Investors in Theranos may lose out and some are filing lawsuits, the Wall Street Journal reports.
Funding and Spending
Nature News looks into health secretary pick Tom Price's views on research funding.
Global Consortium to Conduct Metabolic Phenotyping Research
Research centers in six countries will work on metabolome-related global health challenges including autism, cancer, diabetes, dementia, and obesity.
MDNA Taps Phi Life Sciences to Distribute Prostate Cancer Liquid Biopsy Test in US
MDNA said the arrangement will help it to quickly build a user base and collect post-market data to demonstrate the test's clinical utility.
Interpace Diagnostics Faces Nasdaq Delisting
The company said in a filing with the US Securities and Exchange Commission that it is not in compliance with the exchange's minimum shareholders' equity requirement.
Novogene Raises $75M in Series B Financing Round
The genomic sequencing firm will use the financing to support growth in both the research and clinical NGS market.
Testicular Tumor Genomics Provide Clues to Disease Development, Treatment Resistance
Exome and transcriptome sequences uncovered features that characterized testicular germ cell tumors by whether they did or did not respond to treatment.
Automation, Microsampling Key to Clinical Adoption of Mass Spec-Based Proteomics, Researcher Says
Premium
According to Cedars Sinai Medical Center's Jennifer Van Eyk, mass spec-based proteomics' clinical potential is on the cusp of being realized.
Using enhancements to RT-PCR, the firm is able to detect all protein-coding genes in a single-tube multiplex reaction, reducing costs for large-scale projects.
Penn Cancer Center Taps Tempus to Identify Immunotherapy Response Indicators
Tempus will sequence and analyze pancreatic and melanoma cancer data from Penn patients to identify patterns associated with a positive response to treatment.
Translational Software, DrFirst Ink PGx E-Prescribing Deal
The deal will join Translational Software's genetics-based clinical decision support platform with DrFirst's Rcopia medication management software.
This Week in Genome Biology: Nov 30, 2016
In Genome Biology this week: variants linked to disorders of sex development, new candidate genes for ciliopathies, and more.
Edico Genome, Amazon Web Services Partner on Cloud Bioinformatics
Edico will make its Dragen platform available on new Amazon cloud instances, allowing users to scale up analysis capacity as demand for computing resources grows.
Trovagene, Boreal Genomics to Co-Develop Kits for ctDNA Analysis
The companies will co-develop kits, which Trovagene will distribute globally, to analyze ctDNA from blood or urine using next-generation sequencing platforms.
Mice in Flight
After two months in limbo, a shipment of transgenic mice hops a military flight to the Canary Islands, ScienceInsider reports.
City of Hope, Translational Genomics Research Institute Form Personalized Medicine Alliance
As part of the deal, TGen will also become a subsidiary of City of Hope's parent organization, but will remain a non-profit headquartered in Arizona.
Despite Politics and Budget Limits, Precision Medicine Initiative 'Is Here to Stay,' Says Dishman
Premium
NIH has been conservative on the PMI's budget and its funds are sufficient to launch enrollment next year, begin collecting data, and initiate genetic testing pilot projects.
Evotec Inks Deal to Offer Merck KGaA Gene Editing, Silencing Technologies
Evotec will use Merck's collection of genetic reagents — including viral CRISPR and shRNA libraries — in target discovery programs.
The single-cell approach enabled them to identify gene expression in rare cell types, highlighting a previously unrecognized role for these cells in diabetes.
The company plans to recruit one million patients from Mexico over three years and then expand to Columbia, Argentina, and Brazil.
Phenomenex Clarity LC Columns for Synthetic Oligo Analysis
Phenomenex has launched two new products for characterization and purification of synthetic oligonucleotides, the Clarity Oligo-XT C18 column and the Clarity Oligo-SAX column.
The products will be offered as part of the firm's Clarity BioSolutions portfolio of columns for chromatographic analysis.
The Oligo-XT C18 column is intended for high-efficiency reversed-phase liquid chromatography analysis and purification. Featuring new and robust core-shell media, it offers the separation power to resolve closely related synthetic oligos and the sensitivity to improve quantitation by mass spectrometry. The columns are available in directly scalable 1.7-micrometer, 2.5-micrometer, and 5-micrometer particle sizes.
The Oligo-SAX is a high-resolution strong anion exchanger for characterization, featuring new rugged non-porous particles for improved column lifetimes. It is engineered for performance at high pH and temperatures up to 85° C. It comes in a 5-micrometer particle size for analytical characterization.
Janney Upgrades Veracyte to Buy
The investment bank noted Veracyte's "disciplined" approach to developing and commercializing tests, and said the company stands out in its sector.
Reach of Patients' Voices
NPR reports that patients have ever-larger sway on medical research, but some are concerned about commercial influences.
The Workbench Manager helps labs manage their bioinformatics workflows while the Clinical Annotation software offers clinical variant interpretation services.